CFD
ALXN

Creative Financial Designs’s Alexion Pharmaceuticals ALXN Stock Holding History

Creative Financial Designs’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-251
Closed -$46K – 1482
2021
Q2 		$46K Hold
251
– – 0.01% 628
2021
Q1 		$38K Hold
251
– – 0.01% 630
2020
Q4 		$39K Hold
251
– – 0.01% 564
2020
Q3 		$29K Buy
251
+69
+38% +$7.44K 0.01% 577
2020
Q2 		$20K Buy
+182
New +$19.3K 0.01% 606

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Creative Financial Designs's ALXN Position: Q3 2021 in Review

Creative Financial Designs sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 251 shares — an estimated $46K sold.

Creative Financial Designs first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $46K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Creative Financial Designs reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Creative Financial Designs sold 251 Alexion Pharmaceuticals shares in Q3 2021, an estimated $46K.
  • Creative Financial Designs first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Creative Financial Designs's Alexion Pharmaceuticals position peaked at $46K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Creative Financial Designs's 13F filing for Q3 2021, filed 8 Oct 2021.